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Acute kidney injury (AKI) is associated with progression to
advanced chronic kidney disease (CKD). We tested whether
patients who survive AKI and are at higher risk for CKD
progression can be identified during their hospital admission,
thus providing opportunities to intervene. This was assessed
in patients in the Department of Veterans Affairs Healthcare
System hospitalized with a primary diagnosis indicating AKI
(ICD9 codes 584.xx). In the exploratory phase, three
multivariate prediction models for progression to stage 4
CKD were developed. In the confirmatory phase, the models
were validated in 11,589 patients admitted for myocardial
infarction or pneumonia during the same time frame that
had RIFLE codes R, I, or F and complete data for all predictor
variables. Of the 5351 patients in the AKI group, 728 entered
stage 4 CKD after hospitalization. Models 1, 2, and 3 were all
significant with ‘c’ statistics of 0.82, 0.81, and 0.77,
respectively. In model validation, all three were highly
significant when tested in the confirmatory patients, with
moderate to large effect sizes and good predictive accuracy
(‘c’ 0.81–0.82). Patients with AKI who required dialysis and
then recovered were at especially high risk for progression to
CKD. Hence, the severity of AKI is a robust predictor of
progression to CKD.
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Acute kidney injury (AKI) is a disorder that complicates the
hospital course of patients by exposing them to circulatory
overload, hyperkalemia, metabolic acidosis, neurological
complications, and increased mortality risk.1–6 The incidence
of AKI is increasing, and will nearly double over the next
decade as the population ages. In spite of recent improve-
ments in diagnosis and therapy, the mortality of AKI remains
unacceptably high.5,6 As a result of AKI, patients experience
increased hospital length of stay and may require dialysis.
Population-based studies show that even small acute changes
in serum creatinine (SC) concentration are associated with
poor outcomes.7–10 After accounting for other predictors,
AKI is an independent risk factor for death.11,12
Large population-based studies have demonstrated that
patients who survive an episode of AKI are at considerable
risk for progressing to advanced stages of chronic kidney
disease (CKD).13–16 The population-based incidence of AKI is
estimated at 2147 cases per million population per year.17
Given the US population of 300 million, each year there will
be B600,000 cases of AKI. If 20% of such patients progress
to advanced CKD a year, AKI would be responsible for
120,000 cases of advanced CKD. These data are sobering and
demonstrate the continuity of disease from AKI to CKD to
end-stage renal disease (ESRD). Specifically, we have shown
that up to 20% of patients with an in-patient diagnosis of
acute tubular necrosis (ATN) progress to CKD stage IV or
greater within 18–24 months.13 However, within this same
population, there exists a subset of patients who appear to
achieve near total recovery, and so seem not to progress to
advanced stages of CKD. Therefore, it is likely that some
patients who develop AKI are at higher risk for CKD
progression than others. We hypothesized that if the patients
who survive AKI that are at highest risk for progression to
CKD can be well characterized, opportunities to implement
renoprotective interventions might be realized. It is possible
that if these patients at high risk for CKD progression can be
subjected to close follow-up by nephrologists, the natural
history of this progression might be favorably altered. In
order for this to occur, identification of these patients is
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critical. In this study, we set out to further risk stratify AKI
patients who are more likely to progress to CKD, and develop
a prediction tool to help clinicians identify these patients at
the time of hospital discharge for nephrological outpatient
follow-up.
RESULTS
There were 5351 patients in the AKI population. These
subjects had a mean 10.2±13.9 SC evaluations during the
year before hospitalization, 9.8±7.7 SC evaluations during
their index hospitalization, and 15.0±24.0 after hospitali-
zation. In this group, 728 (13.6%) entered CKD4 after
hospitalization. Of this same group the maximum RIFLE
score was: 299 (5.6%) had no RIFLE score, 845 (15.8%) had
R, 1345 (25.1%) had I, and 2862 (53.5%) had F. Among the
15,917 control (CON) subjects, the mean number of SC
evaluations was 7.4±11.3 during the year before admission,
10.0±8.5 during their index hospitalization, and 14.8±23.7
after the index hospitalization. In the CON group, 1348
subjects (8.5%) entered CKD4 after hospitalization. There were
12,057 CON subjects RIFLE scores with R (75.7%), 2495 with
I (15.7%), and 1365 with F (8.6%) during their hospitalization.
Among CON subjects, 11,589 had complete data for all
predictor variables, and were included in the analysis.
Univariate associations
Among demographic variables, age was associated with
progression to CKD4 (each year of age raised the odds of
entering CKD by 1% (95% confidence interval (CI) 1–2%;
Po0.001), but gender and race were not (Table 1). Need for
dialysis varied between those who entered CKD4 and those
who did not (Po0.0001), with the CKD4 patients more likely
to have required dialysis during their index hospitalization.
Having ATN (as opposed to ARF) diagnosis was associated
with progression to CKD4, raising the odds by 60% (95% CI
21–111%, Po0.001).
Multivariate prediction models for CKD4
In the exploratory phase of the study, we tested various
CKD4 prediction models in the AKI population.
Model 1. This prediction model included: sex, age, race,
diagnosis of ATN, time at risk (T), presence of diabetes
mellitus (DM), estimated glomerular filtration rate (eGFR)-
pre, SC-Hosp, renal replacement therapy (RRT), teaching
hospital, baseline serum albumin concentrations (Alb-Base),
serum albumin during hospitalization (Alb-Hosp), baseline
hemoglobin, and mean-hemoglobin during hospitalization.
The final model was significant (Po0.0001), had moderate
effect size (D¼ 64), and good prediction accuracy (area
under the receiver operating characteristic (ROC) curve¼
0.82; Table 2, Figure 1a). Model parameters were:
y ¼ 0:2141 þ 0:0174  age  0:1861  AA þ 0:1223  T þ 0:1067  DM
þ 0:4075  ðSC-HospÞ  0:5865  ðAlb-BaseÞ  0:8942  ðAlb-HospÞ
The results indicated that each year of age added 2%, having
DM added 24%, and each mg/dl unit increase for SC
during hospitalization (SC-Hosp) added 50% to the odds of
reaching CKD4, African Americans (AAs) had a 31% lower
risk, each gm/dl unit increase in Alb-Base reduced 44%, and
each gm/dl unit increase of Alb-Hosp reduced 59% from the
odds of reaching CKD4. Using the optimal cut-point for the
risk score,18 this model had sensitivity of 0.75 and specifi-
city of 0.73 for predicting CKD4, and the odds ratio (OR)
for a risk score greater than the cut-point was 8.25 (95% CI
6.66–10.23; Table 3).
Model 2. Predictors tested included age, Alb-Hosp,
SC-Hosp, and time at risk. All variables were entered into
the equation. This model was significant (Po0.0001), with
moderate effect size (D¼ 0.61), and good prediction
accuracy (area under the ROC curve¼ 0.81; Figure 1b).
Model parameters were:
y ¼ 0:8249 þ 0:0162  age þ 0:1064  T þ 0:3655  ðSC-HospÞ
 1:1468  ðAlb-HospÞ
According to this model, each year of age raised the odds of
reaching CKD4 by 2%, each 1.0 mg/dl SC increase raised the
odds by 44%, and each 1.0 gm/dl albumin increase reduced
the odds by 68% (Table 4). Risk scores were computed for
each AKI subject using the above equation. Using this risk
score cut-point, the model had a sensitivity of 0.72 and
specificity of 0.74. The odds of reaching CKD4 for those with
a risk score above the cut-point were 7.27 worse (95% CI
5.98–8.84; Table 5) compared with those with risk scores
below the cut-point.
Model 3. Predictors entered into the equation included age,
time at risk, eGFR-Base, RRT, Alb-Hosp, and RIF score.
This model was significant (Po0.0001), and had acceptable
prediction accuracy (D¼ 0.54; area under ROC curve¼ 0.77,
Figure 1c). The prediction model parameters were:
y ¼ 0:0394 þ 0:00959  age þ 0:1165  T  0:00562  ðGFR-BaseÞ
þ 0:4384  RRT þ 0:6326  RIF  1:1214  ðAlb-HospÞ
In this model, each year of age added 1%, each 1 point increase in
RIF score added 88%, and having dialysis during admission
added 140% to the odds of reaching CKD4, each 1 point increase
in GFR-Base reduced the odds by 1%, and each 1-point increase
in Alb-Hosp reduced the odds of reaching CKD4 by 67%
(Table 6). Those with a risk score above the cut-point had odds of
reaching CKD4 that were 5.75 (95% CI 4.72–7.00; Table 7) times
higher than those with scores below the cut-point.
Validation of models in control sample
Model 1. In the CON sample, model 1 was significant
(likelihood ratio w2¼ 1219.8, Po0.0001), with moderate
effect size (D¼ 0.62), and good prediction accuracy (c¼ 0.81;
Figure 2a). ORs for this model indicated that each additional
year of age raised the odds of entering CKD4 by 1%, having
DM raised the odds by 21%, each 1.0 mg/dl increase in SC-
Hosp raised the odds by 582%, being AA reduced the odds by
36%, each additional 1.0 g/dl unit of Alb-Base reduced the
odds by 17%, and each additional 1.0 g/dl unit of Alb-Hosp
reduced the odds by 43%. Risk scores were computed for
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each CON subject using the model 1 equation (Table 8).
Using a cut-point of 2.45, sensitivity was 0.71, specificity
was 0.61, and the OR for CKD4 was 3.85 (95% CI 3.29–4.52).
These results indicate little loss of prediction accuracy in
the validation cohort of patients without a primary AKI
diagnosis compared with the derivation sample of patients
that had a primary AKI diagnosis, in the absence of CKD.
Model 2. Model 2 was significant in the CON population
(Po0.0001), it had moderate effect size (D¼ 0.63), and good
prediction accuracy (c¼ 0.81; Figure 2b). The model
indicated that each year of age added 1%, and each 1.0 g/dl
increase in SC-Hosp added 529% to the odds of reaching
CKD4. Each 1.0 g/dl increase in Alb-Hosp reduced the odds
by 47% (Table 8). Using a risk score cut-point of 2.2, the
model had sensitivity of 0.66, specificity of 0.66, and the odds
of having CKD4 were 3.76 (95% CI 3.28–4.32) for those with
risk scores above, as opposed to below the cut-point.
Model 3. When model 3 was tested in CON subjects, RRT
was found to be highly collinear with the intercept, so this
model was evaluated without the intercept. It was significant
(Po0.0001), had moderate effect size (D¼ 0.64) and good
prediction accuracy (c¼ 0.82; Figure 2c). This model
indicated that each year of age added 1%, and each 1 point
increase in RIF added 343% to the odds of reaching CKD4,
each 1 point increase in GFR-Base reduced the odds of
reaching CKD4 by 3% and each 1.0 g/dl increase of mean
Table 1 | Univariate relationships with CKD4
Variable No CKD4 (n=4623) CKD4 (n=728) Total (N=5351) Univariate odds ratio (95% CI)
n (column %) n (column %)
Race
African American 1444 (31.2) 212 (29.1) 1656 (31.0)
Hispanic 275 (6.0) 57 (7.8) 332 (6.2)
Caucasian 2830 (61.2) 446 (61.3) 3276 (61.2)
Other 74 (1.6) 13 (1.8) 87 (1.6)
Gender
Male 4519 (97.9) 713 (98.6) 5232 (98.0) 1.50 (0.78–2.89) NS
Female 95 (2.1) 10 (1.4) 105 (2.0)
DM pre-admission
Yes 1767 (38.2) 257 (35.3) 2024 (37.8) 1.13 (0.96–1.33), NS
No 2856 (61.8) 471 (64.7) 3327 (62.2)
Dialysis***
Never 4578 (99.0) 690 (94.8) 5268 (98.5)
During hospitalization 39 (0.8) 18 (2.5) 57 (1.1)
Post hospitalization 6 (0.1) 20 (2.8) 26 (0.5)
Hospital complexitya
1A 2493 (54.0) 392 (53.9) 2885 (53.9)
1B 831 (18.0) 126 (17.3) 957 (17.9)
1C 662 (14.3) 98 (13.5) 760 (14.2)
2 469 (10.2) 81 (11.1) 550 (10.3)
3 166 (3.6) 31 (4.3) 197 (3.7)
Teaching hospital
Yes 4080 (88.3) 630 (86.5) 4710 (88.1) 0.85 (0.68–1.07), NS
No 541 (11.7) 98 (13.5) 639 (12.0)
ATN diagnosis**
Yes 276 (6.0) 67 (9.2) 343 (6.4) 1.60 (1.21–2.11)
No 4347 (94.0) 661 (90.8) 5008 (93.6)
Mean±s.d.
Age** 66.1±12.2 67.8±12.6 66.3±12.3 1.01 (1.005–1.02)
Alb-Base*** 3.7±0.6 3.3±0.7 3.61±0.6 0.38 (0.33–0.43)
Alb-Hosp*** 3.3±0.7 2.7±0.7 3.24±0.8 0.31 (0.27–0.36)
Hgb-Base*** 12.9±1.9 12.4±1.8 12.9±1.9 0.86 (0.82–0.89)
Hgb-Hosp*** 11.7±1.9 10.8±1.8 11.6±1.9 0.74 (0.71–0.78)
Residency slots 35.3±18.5 35.8±19.6 35.3±18.7 1.00 (1.00–1.01)
Baseline eGFR 80.4±17.3 81.6±18.1 80.6±17.4 1.00 (1.00–1.01)
Time at risk (years)*** 2.35±1.62 2.79±1.67 2.41±1.6 1.18 (1.12–1.23)
Abbreviations: Alb-Base, baseline serum albumin; Alb-Hosp, serum albumin during hospitalization; ATN, acute tubular necrosis; CI, confidence interval; CKD, chronic kidney
disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; Hgb-Base, baseline serum hemoglobin; Hgb-Hosp, serum hemoglobin during hospitalization; ICU,
intensive care unit; NS, not significant.
*Po0.01 **Po0.001 ***Po0.0001.
aVA hospital complexity is an administrative rating where ‘1’ indicates treatment of high-risk patients, presence of specialty providers, high volume, complex ICU services, and
research.
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albumin during hospitalization reduced the odds by 41%
(Table 8). Having required RRT during admission raised the
risk of entering CKD4 by 5218%. Risk scores were computed
using model 3 in the CON subjects. Using a cut-point of
1.8, the model had sensitivity 0.70, specificity 0.70, and
OR¼ 5.62 for those with risk scores above, as opposed to
below, the cut-point (95% CI 4.87–6.49). These were very
similar to those obtained in the validation cohort when
compared with the derivation sample.
DISCUSSION
Before the era of CKD staging, it was generally accepted that
patients who recovered from AKI had ‘good’ renal outcomes
as assessed by a low incidence of end stage renal disease
(ESRD).19 These previous long-term studies were hampered
by different definitions, variable follow-up times, and low
overall numbers. From 2008 through 2010, four studies
assessing four different cohorts of patients demonstrated that
patients who survive an episode of AKI have a significant risk
for the development of advanced CKD (stage 4/5).13–16 In this
analysis, we were able to identify risk factors for progression
to advanced CKD. Our data suggest that advanced age, low
serum albumin levels, presence of diabetes, and severity of
AKI, as assessed by RIFLE score or mean SC levels during
hospitalization are strong predictors of poor long-term renal
outcome. The strong predictive value of serum albumin levels
is a novel finding, but it is not surprising because these levels
have been associated with poor outcomes in a variety of
diseases including end stage renal disease (ESRD), surgical
illness, and acute stroke.20–22 Low levels of serum albumin
can be due to either nutritional related factors, high levels of
inflammation, or a combination of these factors.23 With
respect to age, a recent meta-analysis indicated that a higher
proportion of elderly survivors of AKI did not recover renal
function as well as younger control subjects.12 Although it is
intuitive that severity of AKI would be associated with
progression to advanced CKD, these data are the first to show
this link (Figure 3). In particular, we have shown that patients
Table 2 | Results model 1 for CKD4
Variable Estimate s.e. P Adjusted OR 95% CI
Intercept 0.2141 0.437 0.62 NA NA
Age 0.0174 0.0047 0.0002 1.02 1.01–1.03
Time at risk 0.1223 0.0405 0.0026 1.13 1.04–1.22
DM 0.1067 0.0585 0.068 1.24 0.98–1.56
SC-Hosp 0.4075 0.0286 o0.0001 1.50 1.42–1.59
African American 0.1861 0.0638 0.0036 0.69 0.54–0.89
Alb-Base 0.5865 0.1033 o0.0001 0.56 0.45–0.68
Alb-Hosp 0.8942 0.0947 o0.0001 0.41 0.34–0.49
Abbreviations: Alb-Base, baseline serum albumin; Alb-Hosp, serum albumin during
hospitalization; CI, confidence interval; CKD, chronic kidney disease; DM, diabetes
mellitus; eGFR, estimated glomerular filtration rate; NA, not applicable; OR, odds ratio;
RRT, renal replacement therapy; SC-Hosp, serum creatinine during hospitalization.
Predictors that were tested included sex, age, race, ATN, time-at-risk, DM, eGFR-Base,
SC-Hosp, RRT, teaching hospital, Alb-Base, Alb-Hosp, mean-hemoglobin-pre, mean-
hemoglobin-during.
Forward selection was used with Po0.1 required to enter the equation. There were
3180 subjects with all data non-missing, who were included in the analysis, 474 of
whom (14.9%) reached CKD4. Somer’s D was 0.64, c=0.82, and likelihood ratio w2 was
565.8 (d.f.=7, Po0.0001).
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Figure 1 |Receiver operating characteristic (ROC) curves for models 1–3 in acute kidney injury (AKI) population. (a) ROC curve for
model 1 in AKI subjects, c¼ 0.82. (b) ROC curve for model 2 in AKI subjects, c¼ 0.81. (c) ROC curve for model 3 in AKI subjects, c¼ 0.77.
Dotted line shows minimum Euclidean distance from ROC curve to the point of optimum sensitivity and specificity.
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who require dialysis are at much higher risk for progression
to CKD than patients with less severe AKI. In the validation
portion of the study, need for RRT increased the likelihood of
progression to CKD by 500-fold (over 5000%). These
findings raise questions about the pathophysiology of AKI
that leads to CKD progression. Pre-clinical studies suggest a
multitude of possible mechanisms: acute endothelial injury
leading to vascular dropout, nephron loss followed by
glomerular hypertrophy, or development of fibrosis after
sustaining AKI.24 To prevent AKI from progressing to CKD,
the pathophysiological mechanisms that underlie this process
will need to be further elucidated.
To make these data accessible to clinicians, we developed
three multivariable models to identify those AKI survivors
who were at highest risk for progression to CKD. Model 1
was developed by stepwise regression and had a rank
correlation between predicted and observed CKD4 of 0.64
(area under ROC curve¼ 0.82). To try and simplify model 1,
we developed model 2, which was based on the most heavily
weighted factors from model 1. This model had a rank
Table 3 | Performance of model 1 in the derivation and
cross-validation samples, at various cut-points
Cut-point
Indicator 3.0 2.5 2.0 1.5 1 0.5 0
In AKI (derivation sample)
Sensitivity 0.96 0.90 0.77 0.64 0.46 0.31 0.20
Specificity 0.37 0.54 0.70 0.83 0.91 0.95 0.97
PPV 0.20 0.25 0.31 0.38 0.46 0.53 0.57
NPV 0.98 0.97 0.95 0.93 0.91 0.89 0.88
Rel risk (pos) 11.73 7.89 5.93 5.61 5.04 4.83 4.63
OR (pos) 14.50 10.17 8.10 8.50 8.46 9.08 9.38
In CON (cross-validation sample)
Sensitivity 0.88 0.72 0.54 0.35 0.18 0.09 0.04
Specificity 0.38 0.59 0.78 0.91 0.97 0.99 1.00
PPV 0.11 0.14 0.18 0.25 0.35 0.48 0.64
NPV 0.97 0.96 0.95 0.94 0.93 0.92 0.92
Rel risk (pos) 4.11 3.45 3.62 4.10 4.89 6.21 8.03
OR (pos) 4.51 3.84 4.21 5.14 6.96 10.95 20.62
Abbreviations: AKI, acute kidney injury; CON, control; NPV, negative predictive value;
OR, odds ratio; PPV, positive predictive value.
Table 4 | Results for model 2 for CKD4
Variable Estimate s.e. P Adjusted OR 95% CI
Intercept 0.8249 0.3661 0.0243 NA NA
Age 0.0162 0.0041 o0.0001 1.02 1.01–1.03
Time at risk 0.1064 0.0341 0.0018 1.11 1.04–1.19
SC-Hosp 0.3655 0.0234 o0.0001 1.44 1.38–1.51
Alb-Hosp 1.1468 0.0707 o0.0001 0.32 0.28–0.37
Abbreviations: Alb-Hosp, serum albumin during hospitalization; CI, confidence
interval; CKD, chronic kidney disease; NA, not applicable; OR, odds ratio; SC-Hosp,
serum creatinine during hospitalization.
Predictors tested included age, Alb-Hosp, SC-Hosp, time-at-risk. All variables were
entered into the equation. There were 4095 subjects with all data non-missing, who
were included in the analysis, 581 of whom (14.2%) reached CKD4. Somer’s D was
0.61, c=0.81, and likelihood ratio w2 was 643.2 (d.f.=4, Po0.0001).
Table 5 | Performance of model 2 in the derivation and
cross-validation samples, at various cut-points
Cut-point
Indicator 3.0 2.5 2.0 1.5 1 0.5 0
In AKI (derivation sample)
Sensitivity 0.96 0.90 0.77 0.62 0.46 0.30 0.17
Specificity 0.33 0.51 0.68 0.82 0.91 0.95 0.98
PPV 0.19 0.23 0.28 0.36 0.45 0.51 0.57
NPV 0.98 0.97 0.95 0.93 0.91 0.89 0.88
Rel risk (pos) 9.75 7.50 5.33 5.07 4.95 4.76 4.66
OR (pos) 11.82 9.49 7.04 7.35 8.12 8.75 9.52
In CON (cross-validation sample)
Sensitivity 0.91 0.77 0.58 0.38 0.20 0.09 0.03
Specificity 0.30 0.53 0.74 0.89 0.97 0.99 1.00
PPV 0.11 0.13 0.17 0.24 0.37 0.53 0.80
NPV 0.97 0.96 0.95 0.94 0.93 0.92 0.92
Rel risk (pos) 4.08 3.49 3.49 3.91 5.19 6.72 9.78
OR (pos) 4.46 3.87 4.01 4.82 7.64 13.11 46.02
Abbreviations: AKI, acute kidney injury; CON, control; NPV, negative predictive value;
OR, odds ratio; PPV, positive predictive value.
Table 6 | Results for model 3 for CKD4
Variable Estimate s.e. P Adjusted OR 95% CI
Intercept 0.0394 0.5192 0.94 NA NA
Age 0.0096 0.0041 0.019 1.01 1.00–1.02
Time at risk 0.1165 0.0328 0.0004 1.12 1.05–1.20
eGFR-Base 0.0056 0.0029 0.052 0.99 0.99–1.00
RRT 0.4384 0.1604 0.0063 2.40 1.28–4.51
RIF score 0.6326 0.0725 o0.0001 1.88 1.63–2.17
Alb-Hosp 1.1214 0.0682 o0.0001 0.33 0.29–0.37
Abbreviations: Alb-Hosp, serum albumin during hospitalization; CI, confidence
interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; NA,
not applicable; OR, odds ratio.
Predictors entered into the equation included age, time-at-risk, eGFR-Base, RRT, Alb-
Hosp, and RIF score (which was coded none=0, R=1, I=2, F=3). There were 4150
subjects with all data non-missing, who were included in the analysis, 582 of whom
(14.0%) reached CKD4. Somer’s D was 0.54, c=0.77, and likelihood ratio w2 was 484.5
(d.f.=6, Po0.0001).
Table 7 | Performance of model 3 in the derivation and
cross-validation samples, at various cut-points
Cut-point
Indicator 3.0 2.5 2.0 1.5 1 0.5 0
In AKI (derivation sample)
Sensitivity 0.98 0.95 0.89 0.77 0.55 0.36 0.16
Specificity 0.15 0.30 0.48 0.64 0.80 0.91 0.97
PPV 0.16 0.18 0.22 0.26 0.31 0.39 0.43
NPV 0.98 0.97 0.96 0.94 0.92 0.90 0.88
Rel risk (pos) 8.15 6.82 6.05 4.68 3.63 3.81 3.49
OR (pos) 9.50 8.10 7.46 5.97 4.79 5.63 5.40
In CON (cross-validation sample)
Sensitivity 0.96 0.87 0.75 0.62 0.44 0.26 0.12
Specificity 0.21 0.42 0.63 0.79 0.91 0.96 0.99
PPV 0.10 0.12 0.16 0.22 0.30 0.40 0.54
NPV 0.98 0.97 0.96 0.96 0.95 0.93 0.92
Rel risk (pos) 6.19 4.32 4.55 5.03 5.60 6.05 7.11
OR (pos) 6.78 4.78 5.22 6.15 7.59 9.46 14.35
Abbreviations: AKI, acute kidney injury; CON, control; NPV, negative predictive value;
OR, odds ratio; PPV, positive predictive value.
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correlation of 0.61 between predicted and observed CKD4
(area under ROC curve¼ 0.81). Model 2 performs well, but
because it includes mean SC-Hosp, its use would be limited
to electronic medical records that can calculate that variable
automatically. Therefore, we developed model 3 for use as a
‘bedside’ model, which is based on sentinel clinical events
(RIFLE stage, need for dialysis, and so on). This model
performs well with a rank correlation of 0.54 between
predicted and observed CKD4 (area under ROC curve¼
0.77). We then tested these equations in a separate large
cohort of hospitalized veterans. All three equations were
significant when tested in the CON populations (Po0.001)
and had c-statistics X0.81, signifying good reproducibility
for all three models. We believe that these equations should
undergo further validation and recalibration in other large
population cohorts. In addition, because these endpoints are
accessible, clinicians can use these equations to risk stratify
AKI survivors who are at highest risk for progression to CKD.
Once fully validated, hospitals with computerized medical
record systems might use software based on prediction
formulas like these, to generate a warning linked to the
patient’s discharge that a particular patient is at risk for
progression to CKD after experiencing an episode of AKI.
This is particularly important when one considers that only a
very small fraction of AKI patients are currently followed by a
nephrologist after discharge.25
Most AKI patients are seen by a primary care provider
following an AKI episode. At 30 days after AKI discharge,
74.5% have seen a primary physician compared with 11.9 and
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Figure 2 |ROC curves for models 1–3 in CON population. (a) ROC curve for model 1 in CON subjects, c¼ 0.81. (b) ROC curve for model 2
in CON subjects, c¼ 0.81. (c) ROC curve for model 3 in CON subjects, c¼ 0.82.
Table 8 | Results of model cross-validation in CON sample
Variable Estimate s.e. P Adjusted OR 95% CI
Model 1
Intercept 4.0348 0.4116 o0.0001 NA NA
Age 0.0108 0.0038 0.0041 1.01 1.003–1.02
Time at risk 0.1630 0.0298 o0.0001 1.18 1.11–1.25
DM 0.0943 0.0430 0.0285 1.21 1.02–1.43
SC-Hosp 1.9199 0.0740 o0.0001 6.82 5.90–7.89
African American 0.4418 0.1068 o0.0001 0.64 0.52–0.79
Alb-Base 0.1903 0.0867 0.0281 0.83 0.70–0.98
Alb-Hosp 0.5614 0.0743 o0.0001 0.57 0.49–0.66
Model 2
Intercept 4.5327 0.3247 o0.0001 NA NA
Age 0.0117 0.0034 0.0006 1.01 1.01–1.02
Time at risk 0.1506 0.0255 o0.0001 1.16 1.11–1.22
SC-Hosp 1.8394 0.0646 o0.0001 6.29 5.55–7.14
Alb-Hosp 0.6316 0.0565 o0.0001 0.53 0.48–0.59
Model 3
Intercept NA NA NA NA NA
Age 0.0058 0.0034 0.088 1.01 1.00–1.01
Time at risk 0.1789 0.0251 o0.0001 1.20 1.14–1.26
RIF (0–3) 1.4881 0.0464 o0.0001 4.43 4.04–4.85
GFR-base 0.0263 0.0023 o0.0001 0.97 0.97–0.98
Alb-Hosp 0.5350 0.0561 o0.0001 0.59 0.53–0.65
RRT 1.9868 0.3955 o0.0001 53.18 11.28–250.64
Abbreviations: AKI, acute kidney injury; Alb-Base, baseline serum albumin; Alb-Hosp,
serum albumin during hospitalization; CON, control; DM, diabetes mellitus; NA, not
applicable; OR, odds ratio; SC-Hosp, serum creatinine during hospitalization.
For each model, the predictor variables used in the AKI sample were entered in a
single step in the CON sample.
Model 1 Likelihood ratio w2 (LRC)=1219.8, d.f.=7, Po0.0001; Somer’s D=0.62, c=0.81.
Model 2 LRC=1470.2, d.f.=4, Po0.0001; Somer’s D=0.63, c=0.81.
Model 3 LRC=10810.0, d.f.=6, Po0.0001; Somer’s D=0.64, c=0.82.
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29.5%, respectively, who see a nephrologist or cardiologist.
Surprisingly, just over one-third of AKI patients who require
dialysis see a nephrologist within 30 days of discharge. This
increases to 48.6% within one year of discharge.25 To our
knowledge, this is the first risk assessment tool for CKD
progression in AKI survivors. If reliable risk stratification
tools can be validated, patients at high risk can be identified
and targeted for intervention and follow-up.
Because our study examined a cohort of patients selected
by ICD-9 codes that may suffer from low sensitivity,4 we
chose to validate our predictive formulas in a large data set of
patients who suffered an episode of AKI based on SC values,
but were not classified as such at discharge. Our results
indicate that the proposed equations may be valuable tools
when applied to all hospitalized patients who experience an
episode of AKI, whether diagnosed or not.
Limitations of this study include its focus on US veterans:
findings may not be representative of other populations,
especially women. In addition, our study excluded patients
with preexisting CKD, so these prediction models may not be
accurate in that population. Our ability to make causal
inferences regarding the effects of predictors on outcomes is
limited. On the other hand, our study strategy allowed us to
access healthcare information for large derivation and
validation samples, and to have long-term follow-up using
both diagnoses and laboratory evaluations.
Because the mechanisms for AKI to CKD progression are
currently unknown, the obvious question remains: when a
survivor of AKI is identified, what measures can be used to
reduce risk of progression to advanced CKD? Progression
may be forestalled by: (1) regular follow-up with serial
creatinine assessment to detect reversible causes of renal
ischemia, (2) rigorous control of blood pressure within
accepted guidelines, and (3) avoidance of medications that
have significant nephrotoxic properties (for example, am-
photericin, NSAIDs). More importantly, we believe that risk
assessment tools such as the ones we propose can be used to
identify patients for clinical trials. We envision a study
wherein AKI survivors at risk for CKD progression are
enrolled into a prospective longitudinal trial. Agents and
interventions that might mitigate the progression to CKD
include but are not limited to: tight blood pressure control,
angiotensin II blockade, low protein diet, HMG Co-A
reductase inhibitors, and anti-proliferative agents. Given the
increasing incidence of AKI in the aging US population,7 we
believe this is a critical issue. More research is needed to gain
insight into the pathophysiology of progression from AKI to
CKD with particular attention to hemodynamically induced
glomerulosclerosis and inflammatory processes that may lead
to scarring and tubular dropout.
In conclusion, we have shown that it is possible to identify
variables that predict CKD progression in an incident AKI
patient population, and that factors, such as AKI severity,
decreased serum albumin concentration, and advanced age,
are associated with progression to CKD after an episode of
AKI. AKI patients who require dialysis and then recover are
at especially high risk for AKI progression, and warrant
follow-up after hospital discharge. We have developed and
validated three equations to risk stratify those survivors of
AKI who are at highest risk for CKD progression. We propose
that these equations be used for identification of patients who
should receive additional follow-up and participate in
interventional clinical trials.
MATERIALS AND METHODS
Subjects included all patients in the Veterans Affairs (VA) healthcare
system who were admitted with a primary diagnosis indicating AKI
(ARF or ATN ICD9 codes 584.xx) during the period 1 October 1999
through 31 December 2005 as previously described.13 For each
subject we recorded all SC, albumin, and other laboratory values
during the year before the index hospitalization, and from the
hospital admission date until either the end of the data collection
period or the patient’s death. eGFR was calculated using the
Modification of Diet in Renal Disease equation.26 Patients with no
SC evaluations before their admission date and patients with
preexisting CKD or any dialysis treatments were removed from the
data set. This was done by removing patients who entered CKD
stage 3, 4, or 5, or whose mean eGFR waso60 ml/min per 1.73 m2,
during the year before index hospitalization. Entry into CKD4
is defined as the first date on which the eGFR decreased below
30 ml/min per 1.73 m2 without ever going above 30 ml/min per
1.73 m2 again for that patient.13 Mean laboratory values were
computed during the baseline year, and during the 30 days after the
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date of hospitalization. Teaching hospital was coded yes when the
number of Medical Residents wasX5 and VA complexity rating was
1 (indicating treatment of high-risk patients, specialty providers,
high volume, complex intensive care unit services, and research).
Time at risk was defined as years from diagnosis date to either the
end of the data collection period or date of death, whichever came
first. Patients in the AKI group had no admissions for myocardial
infarction (MI) or pneumonia (see below).
We first examined univariate associations between the predictors
and outcome using likelihood ratio w2 for categorical variables and
univariate logistic regression models for continuous variables. In the
exploratory phase of the study, we used logistic regression to test
multivariate prediction models for entry into CKD4. Potential
predictors included sex, age, race (AA, Hispanic), diagnosis of ATN,
diagnosis date, presence of DM, mean baseline SC, mean SC-Hosp,
need for RRT during hospitalization (RRT), hospital complexity,
and mean Alb-Base concentrations, mean Alb-Hosp, mean baseline
serum hemoglobin, and mean serum hemoglobin during hospita-
lization. A full-information model was tested including all available
predictor variables (sex, age, race, teaching hospital; DM, baseline
eGFR (GFR-Base), RRT, Alb-Hosp, Alb-Base, baseline serum
hemoglobin, serum hemoglobin during hospitalization, RRT,
and SC-Hosp) using a forward-entry stepwise procedure with a
threshold of Po0.10 to enter the regression equation. For
the equations that were developed, T was time at risk, GFR-Base
was mean eGFR before index hospitalization, RRT was dialysis
during hospitalization (yes¼ 1, no¼ 0), Alb-Hosp was mean
albumin (g/dl) during hospitalization, and RIF was RIFLE score
during hospitalization (coded 0 for none, R¼ 1, I¼ 2, and F¼ 3;
patients requiring dialysis were not coded as RIFLE F, but were
coded separately as requiring dialysis during their index hospitaliza-
tion (RRT)).
In addition to this model, we also tested several more simple a
priori models that might be useful for clinicians who do not have
access to all the predictor variables in our full model. Wald w2 values
were tested to determine whether individual predictor variables had
significant associations with the dependent variable after accounting
for the effects of other predictors in the model. ORs were computed
with 95% Wald confidence intervals. The c statistic (a measure of
area under the ROC curve) was examined as an indicator of overall
prediction accuracy, and Somer’s D was used to indicate the effect
size. This is an estimate of the rank correlation between predicted
and observed CKD4. To test for multi-collinearity, we examined
tolerance and variance inflation using weighted regression, in which
weight was based on the logistic regression maximum likelihood risk
estimate, as recommended by Allison,27 as well as the diagnostics
produced with the ‘collin’ option in SAS Proc Reg. If all tolerances
were40.40 and all condition indices wereo30, we considered this
to indicate that there was no multi-collinearity.
We calculated the optimal cut-point on the ROC curve in the
AKI sample by finding the point on the ROC curve that minimized
the distance from the curve to the point of best prediction (that is,
the point where sensitivity¼ 1 and 1-specificity¼ 0).18 This is the
point on the curve that minimizes the function square root of
([1specificity]2þ [1sensitivity]2). Results are reported as
mean±s.d. unless otherwise noted. Po0.05 was the level of
significance.
Validation of models
To test whether the results of prediction models cross-validated in a
new sample, in the confirmatory phase of the study, we examined all
VA patients who were admitted for MI or pneumonia during the
same time frame as previously described.13 We selected all VA
patients admitted with a primary diagnosis of MI (ICD9 410.xx) or
pneumonia (ICD9 486.xx), who were never admitted for an AKI
diagnosis, and who did not have CKD per the definition above, but
who did have a rise in SC during their index admission that
indicated a RIFLE score of either R, I, or F. We refer to these subjects
as CON. To test a model’s ability to cross-validate in this new sample,
we ran each model that was derived in the AKI sample, in the CON
sample, using the same predictor variables and options. As a first step,
we examined the association between predictors and dependent
variable, the effect size, and the area under the ROC curve.
To further test a model’s ability to cross-validate in the CON
sample, we used the logistic regression parameters that were
generated in the AKI sample, to compute a predicted risk value in
CON patients, based on the formula:
y ¼ int þ b1val1 þ b2val2 þ b3val3 þ . . . þ bnvaln ð1Þ
where int is the intercept, b1 to bn are the parameter estimates in the
regression model, and val1 to valn are the subject’s scores on the
predictor variables. We then examined 2 2 w2 values of predicted
risk versus actual CKD4, for a series of cut-points on y. For each of
these w2 values, we calculated the sensitivity, specificity, positive
predictive value (PPV), negative predictive value (NPV), and OR for
the positive risk score as a predictor for developing CKD4.
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